Mizuho Rates Corbus Pharmaceuticals (CRBP) buy, $34 Price Target

Mizuho maintains its positive outlook on Corbus Pharmaceuticals, setting a $34 price target, a 312.12% upside from the current price.

By EarningsIQ Research Desk · Published Jun 23, 2026, 12:01 PM EDT · Updated Jun 26, 2026, 10:02 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Mizuho rated Corbus Pharmaceuticals Holdings, Inc. ($CRBP) "buy" with a $34 price target on June 23, 2026.

Since the rating, $CRBP is up 10.9% after 1 week, up 10.2% after 1 month and down 46.6% to date (from the $8.46 close on Jun 23, 2026).

CRBP Corbus Pharmaceuticals Holdings, Inc.

$4.52 -42.57% year to date

Daily close · Oct 16, 2026

Key Points

Mizuho reiterated its buy rating for Corbus Pharmaceuticals on June 23, 2026, with a price target of $34.
Mizuho's $34 price target implies 312.12% upside from Corbus Pharmaceuticals Holdings, Inc.'s ($CRBP) current $8.25 share price.
Shares of CRBP traded at $8.31 on Tuesday, with a market cap of approximately $154 million.
Major insiders include Chief Business Officer Nishant Saxena, who acquired shares in early June.

Get $CRBP trade alerts by text

We text you when insiders, Congress or big funds trade $CRBP. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Corbus Pharmaceuticals Holdings, Inc. alert may contain errors. Disclosures

On June 23, 2026, Mizuho reiterated its buy rating for Corbus Pharmaceuticals Holdings, Inc. (NasdaqCM: CRBP), maintaining a price target of $34. Analyst Graig Suvannavejh continues to see potential in the biotechnology firm.

Analyst rating track record

Mizuho vs. the S&P 500

YTD return -21.60% hypothetical

All-time return -34.82% S&P 500 +14.50%

vs. S&P 500 -49.32% behind the index

Hypothetical returns from Mizuho's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Corbus Pharmaceuticals

Several funds have shown varied interest in Corbus Pharmaceuticals. Cormorant Asset Management, LP held steady with 2,344,971 shares valued at about $22 million. Orbimed Advisors LLC increased its stake by 140,000 shares, bringing its total to 1,737,287 shares worth approximately $16.3 million, marking an 8.8% increase. Vanguard Capital Management LLC opened a new position with 734,106 shares valued at around $6.9 million. Meanwhile, Citadel Advisors LLC reduced its holdings by 116,133 shares, now holding 727,060 shares valued at about $6.8 million, a 13.8% decrease.

Corbus Pharmaceuticals Holdings, Inc. Stock Up 10.3%

Shares of NasdaqCM:CRBP traded near $8.31 on Tuesday. Corbus Pharmaceuticals has a market cap of approximately $154 million and a beta of 2.59, indicating higher volatility. The stock's 52-week range is between $6.72 and $20.56, with a 50-day moving average of $9.54 and a 200-day moving average of $10.23. The company, which is not currently profitable, has no meaningful P/E ratio.

12-month forecast

$CRBP price target

Corbus Pharmaceuticals Holdings, Inc. daily closes and this analyst's $34 target. Not advice.

Insider Buying and Selling at Corbus Pharmaceuticals Holdings, Inc.

Several insiders have been active in trading Corbus Pharmaceuticals stock. On June 10, 2026, Jenkins John Kenneth, Winston Kung, and Anne Altmeyer sold shares at an average price of $7.91 as part of planned transactions. Chief Business Officer Nishant Saxena made multiple purchases in early June, acquiring 9,000 shares at $7.58 on June 3, 4,500 shares at $7.33 on June 2, and 58,300 shares on May 21.

Analysts Set New Price Targets

Mizuho maintained its buy rating for Corbus Pharmaceuticals with a $34 target on June 23, 2026. Oppenheimer also maintained its buy rating on June 17, with a higher target of $52. On May 26, HC Wainwright & Co. reiterated a buy rating with a $40 target. The consensus among analysts is a strong buy, with an average price target of $36.30 based on 10 opinions.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapeutics for cancer and obesity. With its headquarters in Norwood, Massachusetts, the company is led by CEO Dr. Yuval Cohen. Corbus is working on CRB-701, an antibody drug conjugate targeting Nectin-4 in cancer cells, and CRB-913 for obesity treatment. Founded in 2009, Corbus employs 36 people.

Bottom Line

Mizuho's reiterated buy rating and $34 price target suggest confidence in Corbus Pharmaceuticals' future prospects. Investors track these analyst opinions closely, but it's important to remember that these ratings are backward-looking. Corbus' focus on innovative treatments in cancer and obesity makes it a company to watch in the healthcare sector.